F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action

Biochemical Pharmacology

Volumn 59, Issue 7, 2000, Pages 807-819

  Perrin, Dominique ^a   Van Hille, Benoît ^a   Barret, Jean Marc ^a   Kruczynski, Anna ^a   Etiévant, Chantal ^a   Imbert, Thierry ^a   Hill, Bridget T ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antitumour agent; Dual catalytic inhibitor; F 11782; Non intercalating agent; Topoisomerase I; Topoisomerase II

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CAMPTOTHECIN; CIBACRON BLUE F3GA; COUMAMYCIN A1; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; F 11782; G 331; GENISTEIN; PODOPHYLLOTOXIN DERIVATIVE; RECOMBINANT ENZYME; SURAMIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CATTLE; DNA CLEAVAGE; DOSE RESPONSE; ENZYME INHIBITION; ENZYME ISOLATION; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; THYMUS;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CATALYSIS; CATTLE; CELL NUCLEUS; DNA; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; ENZYME STABILITY; ETOPOSIDE; EVALUATION STUDIES; HUMANS; NAPHTHALENES; PYRANS; SACCHAROMYCES CEREVISIAE;

EID: 0033962122     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00382-2     Document Type: Article

References (58)

1. Wang J.C. DNA topoisomerases. Annu Rev Biochem. 54:1985;665-697.
2. Liu L.F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 58:1989;351-375.
3. Roca J. The mechanisms of DNA topoisomerases. Trends Biochem Sci. 20:1995;156-160.
4. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 260:1985;14873-14878.
5. Svejstrup J.Q., Christiansen K., Gromova I.I., Andersen A.H., Westergaard O. New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin at a specific recognition site. J Mol Biol. 222:1991;669-678.
6. Pommier Y., Pourquier P., Fan Y., Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta. 1400:1998;83-106.
7. Capranico G., Zunino F. Antitumor inhibitors of DNA topoisomerases. Curr Pharm Des. 1:1995;1-14.
8. Drake F.H., Zimmerman J.P., McCabe F.L., Bartus H.F., Per S.R., Sullivan D.M., Ross W.E., Mattern M.R., Johnson R.K., Crooke S.T., Mirabelli C.K. Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme. J Biol Chem. 262:1987;16739-16747.
9. Drake F.H., Hoffmann G.A., Bartus H.F., Mattern M.R., Crooke S.T., Mirabelli C.K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 28:1989;8154-8160.
10. Tsai-Pflugfelder M., Liu L.F., Liu A.A., Tewey K.M., Whang-Peng J., Knutsen T., Huebner K., Croce C.M., Wang J.C. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA. 85:1988;7177-7181.
11. Austin C.A., Sng J.H., Patel S., Fischer L.M. Novel HeLa topoisomerase II is the IIβ isoform Complete coding sequence and homology with other type II topoisomerases . Biochim Biophys Acta. 1172:1993;283-291.
12. Wasserman R.A., Austin C.A., Fisher L.M., Wang J.C. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases Expression of a functional recombinant human DNA topoisomerase IIα in yeast . Cancer Res. 53:1993;3591-3596.
13. Austin C.A., Marsh K.L., Wasserman R.A., Willmore E., Sayer P.J., Wang J.C., Fischer L.M. Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase IIβ J Biol Chem. 270:1995;15739-15746.
14. Jensen S., Redwood C.S., Jenkins J.R., Andersen A.H., Hickson I.D. Human DNA topoisomerases α and β can functionally substitute for yeast TOP2 in chromosome segregation and recombination. Mol Gen Genet. 252:1996;79-86.
15. Meczes E.L., Marsh K.L., Fisher L.M., Rogers M.P., Austin C.A. Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human Top2β construct allows the study of topoisomerase IIβ inhibitors in yeast. Cancer Chemother Pharmacol. 39:1997;367-375.
16. Woessner R.D., Mattern M.R., Mirabelli C.K., Johnson R.K., Drake F.H. Proliferation- and cell-dependent differences in expression of the 170 kDa and 180 kDa forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2:1991;209-214.
17. Meyer K.N., Kjeldsen E., Straub T., Knudsen B.R., Hickson I.D., Kikuchi A., Kreipe H., Boege F. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. J Cell Biol. 136:1997;775-788.
18. Grue P., Grässer A., Sehested M., Jensen P.B., Uhse A., Straub T., Ness W., Boege F. Essential mitotic functions of DNA topoisomerase IIα are not adopted by topoisomerase IIβ in human H69 cells. J Biol Chem. 273:1998;33660-33666.
19. Turley H., Comley M., Houlbrook S., Nozaki A., Hickson I.D., Gatter K., Harris A.L. The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues. Br J Cancer. 75:1997;1340-1346.
20. Brown G.A., McPherson J.P., Gu L., Hedley D.W., Toso R., Deuchars K.L., Freedman M.H., Goldenberg G.J. Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines. Cancer Res. 55:1995;78-82.
21. Houlbrook S., Addison C.M., Davies S.L., Carmichael J., Stratford I.J., Harris A.L., Hickson I.D. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cell cancer cell lines. Br J Cancer. 72:1995;1454-1461.
22. 4. Br J Cancer. 74:1996;1869-1876.
23. van Hille B., Hill B.T. Yeast cells expressing differential levels of human or yeast DNA topoisomerase II A potent tool for identification and characterization of topoisomerase II-targeting antitumour agents . Cancer Chemother Pharmacol. 42:1998;345-356.
24. Pommier Y. DNA topoisomerase II inhibitors. Teicher B.A. Cancer Therapeutics Experimental and Clinical Agents . 1997;153-174 Humana Press, Totowa, NJ.
25. Imbert T.F. Discovery of podophyllotoxins. Biochimie. 80:1998;207-222.
26. Markovits J., Linassier C., Fossé P., Couprie J., Pierre J., Jacquemin-Sablon A., Saucier J.M., Le Pecq J.B., Larsen A.K. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 49:1989;5111-5117.
27. Andoh T., Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochim Biophys Acta. 1400:1998;155-171.
28. Sorensen B.S., Sinding J., Andersen A.H., Alsner J., Jensen P.B., Westergaard O. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. J Mol Biol. 228:1992;778-786.
29. Roca J., Ishida R., Berger J.M., Andoh T., Wang J.C. Proc Natl Acad Sci USA. 91:1994;1781-1785.
30. Fortune J.M., Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage. J Biol Chem. 273:1998;17643-17650.
31. Yamashita Y., Kawada S.Y., Fujii N., Nakano H. Induction of mammalian topoisomerase I and topoisomerase II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry. 30:1991;5838-5845.
32. Larsen A.K., Grondard L., Couprie J., Desoize B., Comoe L., Jardillier J.C., Riou J.F. The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochem Pharmacol. 46:1993;1403-1412.
33. Riou J.F., Fossé P., Nguyen C.H., Larsen A.K., Bissery M.C., Grondard L., Saucier J.M., Bisagni E., Lavelle F. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. Cancer Res. 53:1993;5987-5993.
34. Utsugi T., Aoyagi K., Asao T., Okazaki S., Aoyagi Y., Sano M., Wierzba K., Yamada Y. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. Jpn J Cancer Res. 88:1997;992-1002.
35. Cain B.F., Baguley B.C., Denny W.A. Potential antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents. J Med Chem. 21:1978;658-668.
36. Baguley B.C., Denny W.A., Atwell G.J., Cain B.F. Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring. J Med Chem. 24:1981;170-177.
37. Suzuki M. SPKK, a new nucleic acid-binding unit of protein found in histone. EMBO J. 8:1989;797-804.
38. Bianchi F., Rousseaux-Prevost R., Bailly C., Rousseaux J. Interactions of human P1 and P2 protamines with DNA. Biochem Biophys Res Comm. 201:1994;1197-1204.
39. Riou J.F., Gabillot M., Philippe M., Schrevel J., Riou G. Purification and characterization of Plasmodium berghei topoisomerases I and II Drug action, inhibition of decatenation and relaxation, and stimulation of cleavage . Biochemistry. 25:1986;1471-1479.
40. Worland S.T., Wang J.C. Inducible overexpression and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae. J Biol Chem. 264:1989;4412-4416.
41. Perrin D., van Hille B., Hill B.T. Differential sensitivities of recombinant human topoisomerase IIα and β to various classes of topoisomerase II interacting agents. Biochem Pharmacol. 56:1998;503-507.
42. Osheroff N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA. Pharmacol Ther. 41:1989;223-241.
43. Pommier Y., Orr A., Kohn K.W., Riou J.F. Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene. Cancer Res. 52:1992;3125-3130.
44. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning A Laboratory Manual . 2nd ed. 1989;Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
45. van Hille B., Lohri A., Reuter J., Hermann R. Nonradioactive quantification of mdr1 mRNA by polymerase chain reaction amplification coupled with HPLC. Clin Chem. 41:1995;1087-1093.
46. Capranico G., Zunino F., Kohn K.W., Pommier Y. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA Relationship with DNA binding affinity and cytotoxicity . Biochemistry. 29:1990;562-569.
47. Carboni M.C., Coderoni S. Effect of CPT on the DNA cleavage/religation reaction mediated by calf thymus topoisomerase I Evidence of an inhibition of DNA religation . Mol Biol Rep. 20:1995;129-133.
48. Coderoni S., Paparelli M., Gianfranceschi G.L. Effect of CPT on the calf thymus topoisomerase I-mediated DNA breakage-reunion reaction Optimal conditions for the formation and reversal of the CPT trapped topoisomerase I cleavable complex . Mol Biol Rep. 17:1993;129-134.
49. Svejstrup J.Q., Andersen A.H., Jakobsen B.K., Jensen A.D., Sørensen B.S., Alsner J., Westergaard O. Techniques to uncouple DNA binding, cleavage, and religation in the catalytic cycles of eukaryotic topoisomerase I and II. Endoh T., Ikeda H., Oguro M. Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy. 1993;95-104 CRC Press Inc, Tokyo, Japan.
50. Osheroff N., Shelton E.R., Brutlag D.L. DNA topoisomerase II from Drosophila melanogaster. J Biol Chem. 258:1983;9536-9543.
51. Benchokroun Y., Couprie J., Larsen A.K. Aurintricarboxylic acid, a putative inhibitor of apoptosis, is a potent inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Biochem Pharmacol. 49:1995;305-313.
52. Corbett A.H., Osheroff N. When good enzymes go bad Conversion of topoisomerase II to a cellular toxin by antineoplasic drugs . Chem Res Toxicol. 6:1993;585-597.
53. Burden D.A., Kingma P.S., Froelich-Ammon S.J., Bjornsti M.A., Patchan M.W., Thomson R.B., Osheroff N. Topoisomerase II-etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J Biol Chem. 271:1996;29238-29244.
54. Lisby M., Krogh B.O., Boege F., Westergaard O., Knudsen B.R. Camptothecins inhibit the utilization of hydrogen peroxide in the ligation step of topoisomerase I catalysis. Biochemistry. 37:1998;10815-10827.
55. Berger J.M., Fass D., Wang J.C., Harrison S.C. Structural similarities between topoisomerases that cleave one or both DNA strands. Proc Natl Acad Sci U S A. 95:1998;7876-7881.
56. Kaufmann S.H. Cell death induced by topoisomerase-targeted drugs More questions than answers . Biochim Biophys Acta. 1400:1998;195-211.
57. Etiévant C., Kruczynski A., Perrin D., Cabrol N., Cassabois V., Chansard N., Hill B.T. In vitro cytotoxic effects of F 11782, a novel catalytic dual inhibitor of topoisomerases I and II. Proc Am Assoc Cancer Res. 40:1999;114.
58. Kruczynski A., Astruc J., Chazottes E., Ricome C., Berrichon G., Imbert T., Colpaert F., Hill B.T. Preclinical antitumour activity of F 11782, a novel catalytic dual inhibitor of topoisomerases I and II. Proc Am Assoc Cancer Res. 40:1999;114.